Avricore Health (TSXV:AVCR) - Aandelenkoers, Nieuws & Analyse

AVCR Overzicht aandelen

Avricore Health Inc. houdt zich bezig met gezondheidsgegevens en point-of-care technologieën in Canada. Meer informatie

AVCR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 30.2% per jaar gegroeid

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( CA$6M )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen zinvolle omzet ( CA$4M )

Avricore Health Inc. Concurrenten

Cloud DX

TSXV:CDX.H

CA$12.1m

Carebook Technologies

TSXV:CRBK

CA$6.2m

Kovo+ Holdings

TSXV:KOVO

CA$6.0m

Hydreight Technologies

TSXV:NURS

CA$25.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avricore Health
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.06
52 Week Hoogtepunt	CA$0.34
52 Week Laag	CA$0.05
Bèta	-1.9
11 maand verandering	-65.71%
3 maanden verandering	-79.66%
1 Jaar Verandering	-64.71%
33 jaar verandering	-64.71%
5 jaar verandering	100.00%
Verandering sinds IPO	-99.61%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AVCR	CA Healthcare Services	CA Markt
7D	-57.1%	0.2%	0.7%
1Y	-64.7%	97.0%	21.7%

Rendement versus industrie: AVCR presteerde slechter dan de Canadian Healthcare Services -sector, die het afgelopen jaar een rendement van 97 % opleverde.

Rendement versus markt: AVCR presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 21.7 % opleverde.

Prijsvolatiliteit

Is AVCR's price volatile compared to industry and market?
AVCR volatility
AVCR Average Weekly Movement	19.2%
Healthcare Services Industry Average Movement	8.1%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van AVCR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 19% ) van AVCR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Canadian.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1996	n/a	Hector Bremner	avricore.com

Avricore Health Inc. houdt zich bezig met gezondheidsgegevens en point-of-care technologieën in Canada. Het bedrijf levert HealthTab, een kant-en-klaar point-of-care testplatform dat apotheken verandert in diagnostische centra in de gemeenschap. Het bedrijf was voorheen bekend als Vanc Pharmaceuticals Inc. en veranderde zijn naam in Avricore Health Inc. in oktober 2018.

Avricore Health Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Avricore Health zich tot de beurswaarde?
AVCR fundamentele statistieken
Marktkapitalisatie	CA$6.06m
Inkomsten(TTM)	-CA$2.92k
Inkomsten(TTM)	CA$4.48m

1.4x

P/S-verhouding

-2,075x

Koers/Winstverhouding

Is AVCR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVCR resultatenrekening (TTM)
Inkomsten	CA$4.48m
Kosten van inkomsten	CA$2.86m
Brutowinst	CA$1.62m
Overige uitgaven	CA$1.62m
Inkomsten	-CA$2.92k

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.000029
Brutomarge	36.16%
Nettowinstmarge	-0.065%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AVCR op de lange termijn?

Bekijk historische prestaties en vergelijking

AVCR Overzicht aandelen

Beloningen

Risicoanalyse

Avricore Health Inc. Concurrenten

TSXV:CDX.H

CA$12.1m

TSXV:CRBK

CA$6.2m

TSXV:KOVO

CA$6.0m

TSXV:NURS

CA$25.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

CTO & Director recently sold CA$51k worth of stock

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Recent updates

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

CTO & Director recently sold CA$51k worth of stock

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

New minor risk - Share price stability

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

New minor risk - Share price stability

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Independent Director exercised options to buy CA$80k worth of stock.

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

New 90-day high: CA$0.27

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

New 90-day high: CA$0.26

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Avricore Health Inc. Samenvatting

1.4x

-2,075x

Inkomsten en omzet